Author: admin als-handoff

SEATTLE, Wash and VANCOUVER, British Columbia, October 27, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the Company will host a Key Opinion Leader (KOL) virtual roundtable event on cytisinicline and smoking cessation on…

October 22, 2020. Dear Fellow Shareholders,. We hope this letter finds you and your families safe and healthy. Given that we continue to live in unprecedented times, faced with uncertainty and unique challenges, John and I thought it was appropriate to reach out with an update on the company’s progress. Achieve remains committed to prioritizing…

SEATTLE, Wash and VANCOUVER, British Columbia, October 8, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced that it has been invited to present at the MicroCap Rodeo Best Ideas Bowl, which is being held…

Designed to Assess the Efficacy and Safety of 3 mg Cytisinicline Three Times Daily Dosing Compared to Placebo. Phase 3 ORCA-2 Trial to Enroll 750 Smokers Across 15 Clinical Trial Sites in the United States. SEATTLE, Wash and VANCOUVER, British Columbia, October 7, 2020 — Achieve Life Sciences, Inc. (NASDAQ: ACHV), a clinical-stage pharmaceutical company…

SEATTLE, Wash. and VANCOUVER, British Columbia, September 30, 2020 – – Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the promotion of John Bencich to Chief Executive Officer. Mr. Bencich has been serving as Achieve’s Chief Financial and Operating…